OncoImmunology

Scope & Guideline

Unraveling the Complex Relationship Between Cancer and Immunity

Introduction

Welcome to your portal for understanding OncoImmunology, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN2162-402x
PublisherTAYLOR & FRANCIS INC
Support Open AccessYes
CountryUnited States
TypeJournal
Convergefrom 2012 to 2024
AbbreviationONCOIMMUNOLOGY / OncoImmunology
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106

Aims and Scopes

OncoImmunology focuses on the intersection of oncology and immunology, emphasizing research that enhances our understanding of cancer immunotherapy and the immune landscape of tumors. The journal aims to disseminate high-quality research that explores novel therapeutic strategies, immune responses to cancer, and the underlying mechanisms of tumor immunology.
  1. Tumor Microenvironment and Immune Interactions:
    Research exploring how the tumor microenvironment influences immune responses and the effectiveness of immunotherapies. This includes studies on immune cell infiltration, cytokine profiles, and the metabolic pathways that modulate immune cell function.
  2. Innovative Immunotherapy Approaches:
    Focus on the development and evaluation of new immunotherapy strategies, such as CAR-T cell therapies, immune checkpoint inhibitors, and oncolytic viruses. The journal emphasizes studies that demonstrate clinical efficacy and mechanistic insights.
  3. Biomarkers and Predictive Models:
    Identification and validation of biomarkers that predict patient responses to immunotherapy. This includes genomic, proteomic, and transcriptomic analyses to develop personalized treatment approaches.
  4. Mechanisms of Immune Evasion:
    Investigating the various mechanisms by which tumors evade immune detection and destruction, including the roles of immune checkpoint molecules, tumor-associated macrophages, and regulatory T cells.
  5. Clinical Trials and Translational Research:
    Reports on clinical trials and translational studies that bridge the gap between laboratory findings and clinical application, aiming to improve patient outcomes through novel immunotherapeutic strategies.
OncoImmunology is at the forefront of cutting-edge research in cancer immunotherapy. Recent publications indicate a significant shift towards innovative approaches and emerging themes that are gaining traction within the field.
  1. Combination Immunotherapy Strategies:
    There is a growing emphasis on combination therapies that integrate various modalities, such as immune checkpoint inhibitors with targeted therapies, to enhance antitumor efficacy and overcome resistance.
  2. Personalized Immunotherapy:
    Research focusing on personalized approaches to immunotherapy is on the rise, including the use of genomic profiling and biomarker-driven strategies to tailor treatments to individual patient needs.
  3. Role of the Microbiome in Cancer Therapy:
    Emerging studies are examining the influence of the microbiome on immune responses to cancer therapies, highlighting its potential role in modulating treatment outcomes.
  4. Innovations in CAR-T Cell Therapy:
    Advancements in CAR-T cell technology, including the development of novel constructs and strategies to enhance their efficacy against solid tumors, are becoming a key area of research.
  5. Cellular Immunotherapy Beyond T Cells:
    Research is expanding to include other immune cell types, such as NK cells and gamma-delta T cells, in immunotherapeutic strategies, recognizing their potential in cancer treatment.

Declining or Waning

While OncoImmunology continues to thrive in various research areas, certain themes appear to be declining in prominence. This decline may reflect shifts in research focus or the maturation of specific fields within cancer immunotherapy.
  1. Basic Science Studies:
    There is a noticeable decrease in purely basic science studies that do not have direct applications to immunotherapy or clinical outcomes. Research is increasingly focused on translational and clinical applications.
  2. Single-Agent Immunotherapies:
    Research on single-agent immunotherapies is waning as the field moves towards combination therapies that leverage multiple mechanisms of action to enhance efficacy and overcome resistance.
  3. Conventional Chemotherapy Integration:
    Investigations into the integration of traditional chemotherapy with immunotherapy have seen a decline, as newer approaches focusing on immune modulation and targeted therapies gain traction.
  4. Animal Models with Limited Relevance:
    Studies utilizing animal models that do not adequately mimic human immune responses or tumor biology are becoming less common, as the field prioritizes more clinically relevant models.

Similar Journals

BMC IMMUNOLOGY

Pioneering Open Access in Immune Studies
Publisher: BMCISSN: Frequency: 1 issue/year

BMC Immunology is a prominent open-access journal published by BMC that has been at the forefront of immunological research since its inception in 2000. Based in the United Kingdom, this journal aims to advance the understanding of immune system functions and disorders through high-quality, peer-reviewed articles. With an impressive scope encompassing various facets of immunology, BMC Immunology has earned a Q3 ranking in the Immunology category according to the 2023 category quartiles, demonstrating its growing impact and relevance in the scientific community. Researchers and professionals will find valuable insights in its array of published works, spanning both foundational studies and innovative applications. The journal's commitment to open access ensures that cutting-edge research is freely available, fostering collaboration and advancement in the field. For those looking to stay updated on the latest developments in immunology, BMC Immunology stands as an essential resource for researchers, professionals, and students alike.

Journal for ImmunoTherapy of Cancer

Pioneering Research for Tomorrow's Cancer Therapies
Publisher: BMJ PUBLISHING GROUPISSN: Frequency: 1 issue/year

Journal for ImmunoTherapy of Cancer, published by the esteemed BMJ Publishing Group, is a leading scholarly journal dedicated to advancing the field of immuno-oncology. Since its inception in 2013, this Open Access journal has emerged as a pivotal platform for disseminating cutting-edge research and innovative methodologies in cancer immunotherapy. With a remarkable impact factor and stellar rankings, including Q1 listings in multiple relevant categories such as Cancer Research, Immunology, and Molecular Medicine, it plays a crucial role in bridging the gap between basic immunology and clinical applications, thus fostering collaboration among researchers, healthcare professionals, and students. The journal's scope encompasses a diverse range of topics, focusing on the latest breakthroughs and experimental findings in cancer treatment, making it indispensable for those seeking to contribute to the evolving landscape of oncological sciences. Located in the United Kingdom at the British Medical Association House, the journal continues to serve as a valuable resource for those at the forefront of cancer research and therapy.

HEMATOLOGICAL ONCOLOGY

Transforming Knowledge into Practice in Hematological Oncology
Publisher: WILEYISSN: 0278-0232Frequency: 4 issues/year

HEMATOLOGICAL ONCOLOGY, published by Wiley, is a premier journal in the fields of cancer research, hematology, and oncology, with a rich history of publication dating back to 1983. With an impact factor indicative of its influential standing—ranking in the second quartile in multiple categories including Cancer Research, Hematology, and Oncology—this journal serves as a vital resource for researchers, clinicians, and students alike. HEMATOLOGICAL ONCOLOGY is based in the United Kingdom and focuses on the advancements and challenges in the understanding and treatment of hematological malignancies. While it does not offer open access options, its rigorous peer-review process ensures that all published articles are of the highest quality, contributing to the ongoing dialogue and research in this critical area of medicine. With its commitment to disseminating impactful research, HEMATOLOGICAL ONCOLOGY remains an essential platform for driving innovation and collaboration within the global scientific community.

IMMUNOLOGICAL INVESTIGATIONS

Advancing Immunology Through Rigorous Research
Publisher: TAYLOR & FRANCIS INCISSN: 0882-0139Frequency: 8 issues/year

IMMUNOLOGICAL INVESTIGATIONS, published by Taylor & Francis Inc, is a leading journal in the field of immunology and related medical sciences, with an established presence since 1972. With a focus on cutting-edge research and critical insights in immunological methods and theories, this journal serves as a pivotal platform for researchers, professionals, and students alike. Though it currently holds a Q3 ranking in Immunology and a Q2 ranking in miscellaneous medicine as of 2023, its Scopus rank of #129 out of 236 reflects its dedication to advancing the understanding of immune responses and therapies. The journal's commitment to rigorous peer review and high-quality publications enables it to remain relevant and influential in the ever-evolving landscape of immunological research. Subscription is required to access its extensive archive, which spans critical developments in the field of immunology from 1972 to 2024.

INTERNATIONAL JOURNAL OF ONCOLOGY

Advancing cancer research for a healthier tomorrow.
Publisher: SPANDIDOS PUBL LTDISSN: 1019-6439Frequency: 12 issues/year

INTERNATIONAL JOURNAL OF ONCOLOGY is a leading academic publication dedicated to advancing the field of cancer research and treatment. Published by SPANDIDOS PUBL LTD in Greece, this journal, with ISSN 1019-6439 and E-ISSN 1791-2423, has established itself as a reputable source of peer-reviewed articles since its inception in 1993. With an impressive Q2 ranking in both Cancer Research and Oncology categories, as well as high Scopus ranks reflecting its significant contribution to the fields of Medicine and Biochemistry, the journal offers a platform for researchers, clinicians, and students alike to disseminate their findings and engage in dialogue surrounding innovative practices and breakthroughs. Although the journal follows a traditional subscription model, it continues to attract a diverse readership interested in the latest developments in oncological research, providing essential insights into cancer biology, therapeutics, and patient care. With a commitment to excellence, the INTERNATIONAL JOURNAL OF ONCOLOGY plays a vital role in shaping the future of oncology research and is a must-read for anyone passionate about advancing cancer treatment and prevention.

JOURNAL OF EXPERIMENTAL MEDICINE

Fostering Collaboration for Groundbreaking Research
Publisher: ROCKEFELLER UNIV PRESSISSN: 0022-1007Frequency: 12 issues/year

JOURNAL OF EXPERIMENTAL MEDICINE, published by Rockefeller University Press, is a renowned peer-reviewed journal dedicated to advancing the field of experimental medicine since its inception in 1896. With an impressive impact factor and categorized in the Q1 quartile for Immunology, Immunology and Allergy, and Miscellaneous Medicine, this journal stands at the forefront of medical research and innovation. It provides a prestigious platform for scholars and practitioners to disseminate groundbreaking findings that drive the understanding of disease mechanisms and therapeutic strategies. While the journal is not open access, it maintains high visibility and engagement within the scientific community, fostering collaboration among researchers, professionals, and students alike. The journal's consistent ranking in the top percentiles of Scopus illustrates its significant impact and commitment to excellence in medical research.

Immunity Inflammation and Disease

Championing open science in the study of immune mechanisms.
Publisher: WILEYISSN: Frequency: 12 issues/year

Immunity, Inflammation and Disease is a premier open-access journal published by WILEY, dedicated to advancing the field of immunology and allergy. Launched in 2013, this journal has established itself as a significant platform for researchers and professionals to disseminate high-quality research findings and innovative insights that address critical issues in immune responses and inflammatory diseases. With an impact factor that reflects its growing influence and a current ranking in Q3 for Immunology and Q2 for Immunology and Allergy, this journal serves a diverse audience keen on exploring cutting-edge developments. Researchers are encouraged to submit their work to share their findings with a global reach, foster collaboration, and enhance the understanding of immune mechanisms and therapeutic strategies. Accessible since its inception, Immunity, Inflammation and Disease is committed to open science, ensuring that vital research is freely available for the advancement of knowledge within the academic community and beyond.

Molecular Therapy Oncolytics

Exploring the Frontiers of Molecular Medicine in Oncology
Publisher: CELL PRESSISSN: 2372-7705Frequency: 1 issue/year

Molecular Therapy Oncolytics is an esteemed Open Access journal published by CELL PRESS, focusing on cutting-edge research in the fields of oncology, molecular medicine, and pharmacology. Established in 2014, the journal has quickly gained a prominent position in the academic community, reflected in its impressive Q1 and Q2 rankings across various categories including Cancer Research, Molecular Medicine, and Pharmacology. With an impactful presence in the UK and a strong international readership, it aims to disseminate significant advancements in therapeutic strategies targeted at cancer treatment and management. By providing a platform for peer-reviewed research, Molecular Therapy Oncolytics plays a critical role in bridging the gap between scientific innovation and clinical application, making it an invaluable resource for researchers, healthcare professionals, and students striving to contribute to the evolving landscape of oncology.

GENE THERAPY

Pioneering Innovations in Genetic Healing
Publisher: SPRINGERNATUREISSN: 0969-7128Frequency: 12 issues/year

GENE THERAPY, published by SpringerNature, is a prestigious academic journal at the forefront of research in the fields of genetics, molecular biology, and molecular medicine. Since its inception in 1994, this journal has evolved into a vital resource for scholars, practitioners, and students, providing cutting-edge insights into gene therapy techniques and innovations. With an impressive impact factor reflecting its significant influence— ranking in the Q1 quartile across multiple categories in 2023—GENE THERAPY offers rigorous peer-reviewed articles that address both basic and applied aspects of gene therapy. The journal is recognized for its role in promoting advancements in therapeutic strategies, thus enhancing understanding of genetic disorders and treatment efficacy. Researchers will find this journal invaluable for publishing their findings, staying updated on the latest breakthroughs, and fostering interdisciplinary collaborations. Engage with the latest in gene therapy by accessing this influential platform, and contribute to a field that holds the potential to transform healthcare outcomes worldwide.

Kidney Cancer

Fostering global dialogue in kidney cancer advancements.
Publisher: IOS PRESSISSN: 2468-4562Frequency: 2 issues/year

Kidney Cancer, published by IOS PRESS, is an esteemed open-access journal dedicated to advancing knowledge in the field of nephrology and oncology. Since its inception in 2017, this journal has provided a dynamic platform for researchers, practitioners, and students to disseminate their findings and discuss innovative approaches to kidney cancer treatment and research. With an ongoing commitment to fostering collaboration and sharing critical insights, Kidney Cancer aims to bridge gaps in understanding and promote new methodologies in patient care. Despite its current ranking in the lower quartiles of its category, the journal is positioned to make significant contributions to the academic community by publishing high-quality, peer-reviewed articles that enhance the discourse in kidney cancer research. Furthermore, its open-access model ensures that valuable research is accessible to a global audience, supporting the urgent need for advancements in this critical area of health. Join the conversation and contribute to the growing body of knowledge in this vital field.